Blinatumomab + Chemo Ups Survival in B-Cell Precursor Acute Lymphoblastic Leukemia
By Elana Gotkine HealthDay Reporter
MONDAY, July 29, 2024 -- For adult patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) who have measurable residual disease (MRD)-negative remission, blinatumomab in addition to consolidation chemotherapy is associated with improved overall survival, according to a study published in the July 25 issue of the New England Journal of Medicine.
Mark R. Litzow, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a phase 3 trial involving patients aged 30 to 70 years with BCR::ABL1-negative BCP-ALL (:: indicating fusion) who had MRD-negative remission after induction and intensification chemotherapy. Of the 224 patients, 112 were randomly assigned to receive four cycles of blinatumomab in addition to four cycles of consolidation chemotherapy, and 112 were assigned to receive four cycles of consolidation chemotherapy alone.
The researchers found that at a median follow-up of 43 months, there was an advantage in the blinatumomab group versus the chemotherapy-only group with respect to overall survival (85 versus 68 percent at three years; hazard ratio for death, 0.41) and in three-year relapse-free survival (80 versus 64 percent; hazard ratio for relapse or death, 0.53). Compared with the chemotherapy-only group, the incidence of neuropsychiatric events was higher in the blinatumomab group.
"We found a significant improvement in overall survival among patients 30 to 70 years of age who had an MRD-negative remission of BCP-ALL and received blinatumomab plus chemotherapy in consolidation, as compared with chemotherapy alone," the authors write.
The study was partly funded by Amgen, the manufacturer of blinatumomab.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma
MONDAY, Oct. 7, 2024 -- For patients with relapsed/refractory large B-cell lymphoma (LBCL), the autologous, CD19-directed, 4-1BB chimeric antigen receptor T-cell product...
Measurable Residual Disease Results After Consolidation Therapy Predictive of Relapse in Pediatric Leukemia
TUESDAY, Sept. 24, 2024 -- For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to...
Genetic Subtype, Genomic Alterations Linked to Relapse in Leukemia
THURSDAY, Aug. 22, 2024 -- Genetic subtype, aneuploidy patterns, and genomic alterations are associated with the risk for relapse in childhood acute lymphoblastic leukemia (ALL)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.